Evidence map›Paper›PMID 41703114›Full record

SynthesisScientific reports2026

A meta-analysis identifies driver genes and characterizes the molecular epidemiology of colorectal cancer.

Sigurgeir Olafsson, Thorri Thorarinsson, Sigurjon A Gudjonsson, Mariana Bustamante, Helga S Gunnarsdottir, Hildur Knutsdottir, Hakon Jonsson, Magnus I Magnusson, Emilia Soebech, Hjaltey Runarsdottir and 13 more

Abstract readMeta-Analysis
In one paragraph

Synthesis in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Sigurgeir OlafssonAmgen deCODE Genetics, Reykjavik, Iceland. sigurgeo@decode.is.
Thorri ThorarinssonAmgen deCODE Genetics, Reykjavik, Iceland.
Sigurjon A GudjonssonAmgen deCODE Genetics, Reykjavik, Iceland.
Mariana BustamanteAmgen deCODE Genetics, Reykjavik, Iceland.
Helga S GunnarsdottirDepartment of Pathology, Landspitali University Hospital, Reykjavik, Iceland.
Hildur KnutsdottirAmgen deCODE Genetics, Reykjavik, Iceland.
Hakon JonssonAmgen deCODE Genetics, Reykjavik, Iceland.
Magnus I MagnussonAmgen deCODE Genetics, Reykjavik, Iceland.
Emilia SoebechAmgen deCODE Genetics, Reykjavik, Iceland.
Hjaltey RunarsdottirAmgen deCODE Genetics, Reykjavik, Iceland.
Droplaug N MagnusdottirAmgen deCODE Genetics, Reykjavik, Iceland.
Louise le RouxAmgen deCODE Genetics, Reykjavik, Iceland.
Jona SaemundsdottirAmgen deCODE Genetics, Reykjavik, Iceland.
Bjarney S KristinsdottirDepartment of Pathology, Landspitali University Hospital, Reykjavik, Iceland.
Bjarni A AgnarsonDepartment of Pathology, Landspitali University Hospital, Reykjavik, Iceland.
Erna M JonsdottirDepartment of Pathology, Landspitali University Hospital, Reykjavik, Iceland.
Thordur TryggvasonDepartment of Pathology, Landspitali University Hospital, Reykjavik, Iceland.
Magnus O UlfarssonAmgen deCODE Genetics, Reykjavik, Iceland.
Daniel F GudbjartssonAmgen deCODE Genetics, Reykjavik, Iceland.
Jon G JonassonDepartment of Pathology, Landspitali University Hospital, Reykjavik, Iceland.
Olafur MagnussonAmgen deCODE Genetics, Reykjavik, Iceland.
Kari StefanssonFaculty of Medicine, University of Iceland, Reykjavik, Iceland.
Thorunn RafnarAmgen deCODE Genetics, Reykjavik, Iceland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer is thought to develop through the stepwise accumulation of somatic mutations. Recent years have seen the publications of several studies greatly advancing our understanding of the molecular events driving the disease. However, individual studies tend to be small and additional insights may be obtained through the combination of data from multiple sources. We performed targeted sequencing of 2172 colorectal cancers from Icelandic patients and combined these data with publicly available mutation calls from 9 515 additional tumours collected from the literature. Analysing microsatellite stable (MSS) and instable (MSI) tumours separately, we find evidence of positive selection of mutations in 112 genes that replicate across multiple studies of patients with diverse demographics. We carried out a meta-analysis of conditional selection, identifying 57 gene pairs where a mutation in one gene influences the selection of the other. We describe many associations with tumour phenotypes, including a strong association between mucinous histology and mutations in the transcription growth factor beta (TGFb) pathway, only in MSS tumours. Our study demonstrates how combining evidence from multiple sources allows for new discoveries in cancer genomics.

Indexed as

Colorectal NeoplasmsHumansIcelandMicrosatellite InstabilityMolecular EpidemiologyMutation

Identifiers

PMID41703114
PMCPMC13003110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.